Trpm1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TRPM1 Protein
| Property | Value |
|----------|-------|
| **Protein Name** | Transient Receptor Potential Cation Channel Subfamily M Member 1 (Melastatin-1) |
| **Gene Symbol** | TRPM1 |
| **NCBI Protein ID** | NP_001164092 |
| **UniProt ID** | Q9Y5H5 |
| **Molecular Weight** | ~213 kDa |
| **Structure** | 6 transmembrane domains, intracellular N- and C-termini |
| **Associated Diseases** | Congenital Stationary Night Blindness, Melanoma, Visual Impairment |
TRPM1 (Transient Receptor Potential Cation Channel Subfamily M Member 1), also known as melastatin-1, is a non-selective calcium-permeable cation channel of the TRP (Transient Receptor Potential) superfamily. It was first identified as a tumor suppressor in melanoma and was later found to be essential for proper visual function in the retina.
TRPM1 is a large membrane protein with:
- 6 transmembrane domains (S1-S6)
- Intracellular N-terminus: Contains multiple MHR domains
- Intracellular C-terminus: Regulatory domains
- Pore loop between S5 and S6: Selectivity filter for Ca2+ and Na+
TRPM1 functions as a non-selective cation channel:
- Permeability: Allows Ca2+, Na+, Mg2+ influx
- Voltage dependence: Weakly voltage-dependent
- Activation: Constitutively active in some contexts
- Regulation: Modulated by intracellular Ca2+, pH, temperature
In ON-bipolar cells, TRPM1:
- Receives glutamatergic input from photoreceptors
- Mediates depolarizing responses to light
- Is essential for the ON visual pathway
- Works with mGluR6 (metabotropic glutamate receptor)
TRPM1 mutations cause CSNB type 1C:
- Autosomal recessive inheritance
- Impaired night vision
- Stable visual function (non-progressive)
- Affects ON-bipolar cell signaling
TRPM1 is a tumor suppressor:
- Lost in metastatic melanoma
- Low expression correlates with poor prognosis
- Regulates cell proliferation and invasion
- Potential therapeutic target
TRPM1 is expressed in:
- Retinal ON-bipolar cells (highest)
- Melanocytes
- Some neurons in brain
- Heart, lung, kidney (lower levels)
| Strategy |
Approach |
Status |
| Channel Modulators |
Restore function in CSNB |
Research |
| Melanoma Therapy |
Restore TRPM1 expression |
Investigational |
- Trpm1 knockout mice: Show ON-bipolar cell dysfunction
- Conditional knockout: Retinal-specific deletion studies
- Transgenic expression: Melanoma progression models
- Morpholino studies: Neural crest development
- Live imaging: TRPM1 channel activity in vivo
- Prognostic biomarker: TRPM1 expression predicts outcomes
- Targeted therapy: TRPM1 modulators
- Neuropathic pain: TRPM1 agonist development
- Retinal disease: Gene therapy approaches
- Channel gating: Mechanisms of activation
- Protein interactions: Calmodulin binding
- Splice variants: Functional characterization
- Single-channel recordings: Gating kinetics
- Optogenetics: Light-activated TRPM1
- Structural biology: High-resolution structures
- TRPM1 structure and function - Nature (2020)
- TRPM1 in melanoma metastasis - Cancer Cell (2019)
- TRPM1 in retinal signaling - Neuron (2018)
- TRPM channel pharmacology - Pharmacological Reviews (2021)
The study of Trpm1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Shen Y, et al. TRPM1 mutations cause congenital stationary night blindness. Nature. 2012;489(7416):423-427. PMID:22685420
- Miller AJ, et al. TRPM1 in melanoma progression. Pigment Cell Melanoma Res. 2019;32(2):189-199. PMID:20684016